{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002752","form_type":"8-K","ticker":"OBIO","cik":"0001814114","company_name":"Orchestra BioMed Holdings, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.274958+00:00","generated_at":"2026-05-16T10:55:45.737695+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Orchestra BioMed to receive up to $21M from Haemonetics' acquisition of Vivasure","bullets":["Expects $11M in 2026 proceeds: ~$5M upfront + ~$6M first milestone payment.","Remaining up to $10M from future revenue earnouts based on milestone achievement.","Vivasure's PerQseal Elite received CE Mark and filed PMA with FDA; 0% major complications at 30 days.","Haemonetics closed acquisition on January 9, 2026; OBIO was strategic holder since formation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002752","json":"https://secwatch.observer/filing/0001104659-26-002752.json","markdown":"https://secwatch.observer/filing/0001104659-26-002752.md","text":"https://secwatch.observer/filing/0001104659-26-002752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1814114/000110465926002752/0001104659-26-002752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1814114/000110465926002752/tm262832d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:55:45.737695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}